Oral miltefosine for leishmaniasis in immunocompromised patients: Compassionate use in 39 patients with HIV infection

Clinical Infectious Diseases

Volumn 39, Issue 10, 2004, Pages 1520-1523

  Sindermann, Herbert ^a,c   Engel, Kirsten R ^b   Fischer, Christina ^a   Bommer, Wolfgang ^b  

^a Research and Development   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c Zentaris GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MILTEFOSINE;

ADULT; ANOREXIA; ARTICLE; CLINICAL ARTICLE; DIARRHEA; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; LEISHMANIASIS; MALE; NAUSEA; PRIORITY JOURNAL; RELAPSE; SIDE EFFECT; TREATMENT FAILURE; VOMITING;

ADMINISTRATION, ORAL; ADULT; ANTIPROTOZOAL AGENTS; FEMALE; HIV INFECTIONS; HUMANS; IMMUNOCOMPROMISED HOST; LEISHMANIASIS; MALE; MIDDLE AGED; PHOSPHORYLCHOLINE;

EID: 8744267605     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/425359     Document Type: Article

References (12)

1. World Health Organization (WHO). Leishmania/HIV co-infection in south-western Europe 1990-1998: retrospective analysis of 965 cases. WHO/Leish/2000/2000.42.
2. Bryceson A. A policy for leishmaniasis with respect to the prevention and control of leishmaniasis. Trop Med Int Health 2001; 6:928-34.
3. Laguna F. Treatment of leishmaniasis in HIV-positive patients. Ann Trop Med Parasitol 2003; 97(Suppl 1):135-42.
4. Rosenthal E, Marty P. Recent understanding in the treatment of visceral lesihmaniasis. J Postgrad Med 2003; 49:61-8.
5. Kuhlencord A, Maniera T, Eibl H, Unger C. Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice. Antimicrob Agents Chemother 1992; 36:1630-4.
6. Sindermann H, Croft SL, Engel KR, et al. Miltefosine (Impavido): the first oral treatment against leishmaniasis. Med Microbiol Immunol (Bed) 2003;26 September [E-published ahead of print].
7. Jha TK, Sundar S, Thakur CP, et al. Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. N Engl J Med 1999; 341: 1795-800.
8. Sundar S, Jha TK, Thakur CP, et al. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 2002; 347:1739-46.
9. Soto J, Toledo J, Gutierrez P, et al. Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent. Clin Infect Dis 2001; 33: E57-61.
10. Murray HW, Delph-Etienne S. Visceral leishmanicidal activity of hexadecylphosphocholine (miltefosine) in mice deficient in T cells and activated macrophage microbicidal mechanisms. J Infect Dis 2000; 181: 795-9.
11. Murray HW. Suppression of posttreatment recurrence of experimental visceral leishmaniasis in T-cell-deficient mice by oral miltefosine. Antimicrob Agents Chemother 2000; 44:3235-6.
12. Thakur CP, Sinha PK, Singh RK, et al. Miltefosine in a case of visceral leishmaniasis with HIV co-infection; and rising incidence of this disease in India. Trans R Soc Trop Med Hyg 2000; 94:696-7.